The Physiological Impact of Amylin in Glucose Homeostasis

Pancreatic β-cells co-secrete amylin, a 37-amino-acid peptide hormone, alongside insulin in response to nutrient intake. This hormone plays a fundamental role in maintaining amylin in glucose homeostasis by modulating several metabolic pathways. Specifically, amylin suppresses postprandial glucagon secretion, which reduces hepatic glucose output. Furthermore, it slows gastric emptying to prevent rapid glucose spikes and promotes satiety via central nervous system pathways. Consequently, these combined actions optimize insulin sensitivity and help regulate overall energy balance in healthy individuals.

The Pathogenic Paradox: Amyloid Fibrils and β-Cell Dysfunction

While physiological levels of amylin support metabolic health, high concentrations often correlate with detrimental effects in Type 2 Diabetes (T2D). Chronic hypersecretion of amylin leads to the formation of amyloid fibrils within the pancreatic islets. These aggregates exert cytotoxic effects on β-cells, potentially driving the progression of the disease. Therefore, amylin presents a paradox where it acts as both a protective regulator and a pathogenic factor. Research indicates that the transition from monomeric amylin to toxic oligomers significantly impairs β-cell survival and worsens insulin resistance over time.

Advancing Diabetes Care: Leveraging Amylin in Glucose Homeostasis

Despite the risks associated with amyloidogenesis, synthetic amylin analogues offer significant therapeutic benefits. Medications like pramlintide mimic the hormone's beneficial actions without the risk of aggregate formation. These analogues effectively improve glycemic control, facilitate weight loss, and enhance energy expenditure. Moreover, emerging therapies now target dual activation of amylin and calcitonin receptors in the hypothalamus to maximize metabolic benefits. However, clinicians must balance these therapeutic advantages against concerns regarding long-term safety and potential β-cell toxicity. Future clinical trials remain essential to refine these treatments for broader use in T2D management.

Frequently Asked Questions

How does amylin regulate blood sugar levels?

Amylin works alongside insulin to control postprandial glucose. It inhibits the release of glucagon from the liver and slows the rate at which the stomach empties, ensuring a more gradual absorption of nutrients into the bloodstream.

Why is amylin considered a \"double-edged sword\" in diabetes?

In low to normal concentrations, it protects metabolic health. However, at high concentrations seen in insulin-resistant states, it forms toxic amyloid deposits that can destroy insulin-producing cells and accelerate diabetes progression.

What are the benefits of amylin analogues in clinical practice?

Amylin analogues help patients achieve better HbA1c levels and promote weight loss. They are particularly useful for managing post-meal blood sugar surges that insulin alone may not fully control.

Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice or a substitute for professional healthcare consultation. Refer to the latest local and national guidelines for clinical practice.

References

Almasoudi SH et al. Amylin role in glucose homeostasis and β-cell function: a robust justification. Minerva Endocrinol (Torino). 2026 Mar 13. doi: 10.23736/S2724-6507.26.04508-2. PMID: 41823980.

Pilsniak A. Role of Amylin in Glucose Homeostasis. Austin Publishing Group. 2019.

Alanazi M et al. The protective effect of amylin in type 2 diabetes: Yes or no. Eur J Pharmacol. 2025 Jun 5;996:177593. doi: 10.1016/j.ejphar.2025.177593.